

1 **Awareness about the risk of hearing loss after ototoxic**
2 **treatments in Swiss childhood cancer survivors**

3 **1. Authors**

4 Philippa Jörger^{1,2}, Carina Nigg¹, Maša Žarković^{1,2}, Grit Sommer¹, Martin Kompis³,
5 Gisela Michel⁴, Marc Ansari^{5,6}, Nicolas Waespe^{1,5,7}, Claudia E. Kuehni^{1,7}✉
6

7 **1.1 Affiliations**

- 8
- 9 1. Institute of Social and Preventive Medicine, University of Bern, Bern,
10 Switzerland
 - 11 2. Graduate School for Health Sciences, University of Bern, Bern,
12 Switzerland
 - 13 3. Department of ENT, Head and Neck Surgery Inselspital, University
14 Hospital Bern and University of Bern, Bern, Switzerland
 - 15 4. Faculty of Health Sciences and Medicine University of Lucerne, Lucerne,
16 Switzerland
 - 17 5. CANSEARCH research platform in pediatric oncology and hematology,
18 Department of Pediatrics, Gynecology and Obstetrics, University of
19 Geneva, Geneva, Switzerland
 - 20 6. Department of Women, Child and Adolescent, Division of Pediatric
21 Oncology and Hematology, Geneva University Hospital, University of
22 Geneva, Geneva, Switzerland
 - 23 7. Division of Pediatric Hematology/Oncology, Department of Pediatrics,
24 Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
25

26
27 ✉ **Corresponding author:**

28 Correspondence to:

29 Claudia E. Kuehni, Prof. MD;

30 Institute of Social and Preventive Medicine, University of Bern,

31 Mittelstrasse 43, 3012 Bern, Switzerland;

32 email: claudia.kuehni@unibe.ch; Telephone: +41 31 684 35 07
33

It is made available under a [CC-BY 4.0 International license](#) .

Manuscript – Awareness Hearing loss
25-Sep-24

Philippa Jörger

34

35 **2. Abstract**

36 **Objectives:** The International Guideline Harmonization Group recommends
37 childhood cancer survivors (CCS) exposed to ototoxic treatments be aware of the
38 risk of hearing loss. We assessed awareness among adult CCS.

39 **Methods:** We identified adults diagnosed with cancer <20 years who received
40 ototoxic treatments through the Swiss Childhood Cancer Registry (ChCR) and
41 invited them to the HEAR-study. Participants completed a questionnaire and
42 underwent pure-tone audiometry. Cancer and treatment data came from the
43 ChCR. We used logistic regression to explore factors influencing awareness.

44 **Results:** 105 of 424 invited CCS participated (25%). 57% did not remember
45 receiving information on hearing loss prior to the study. CCS who remembered
46 being informed were more likely diagnosed after 1995 (OR: 4.5, 95% CI: 1.3-
47 15.4), reported hearing problems (10.9, 2.6-45.1) and other late effects (4.1, 1.3-
48 13.2), and treated with platinum chemotherapy only (10.8, 2.2-53.2) versus
49 cranial radiotherapy only. 44% of participants presented clinically relevant
50 hearing loss.

51 **Conclusions:** Over half of CCS exposed to ototoxic treatments were unaware of
52 their risk of hearing loss.

53 **Practice Implications:** Educating CCS about potential late effects of ototoxic
54 treatments is important to allow early diagnosis and treatment, especially for
55 those who had cancer longer ago and those exposed to cranial radiation.

56

57 **Keywords (7):** hearing problems, childhood cancer survivors, awareness, late-
58 effects, ototoxicity, information provision

59

60 **Highlights:**

- 61 • Half of CCS exposed to ototoxic treatment were unaware of the risk of
62 hearing loss
- 63 • CCS treated before 1995 were less aware about the risk of hearing loss
- 64 • Information provision is key to effective monitoring and early intervention

65

66 **3. Introduction**

67 Childhood cancer survivors (CCS) are at risk of hearing loss as a late effect of
68 certain treatments [1]. Forty percent of CCS treated with platinum chemotherapy,
69 around 20% of those treated with doses of cranial radiation ≥ 30 gray (Gy), and
70 varying proportions of those treated with surgery involving the auditory system
71 experience hearing loss [1–6]. Cumulative incidence of hearing loss due to these
72 treatments increases up to 15 years after completing cancer treatment [7].
73 Among CCS, undetected hearing loss can impair language development, school
74 performance, neurocognitive functions, and overall quality of life [8–11]. Regular
75 audiometric screening enables hearing loss to be detected as early as possible
76 and allows appropriate measures to be initiated. The International Guideline
77 Harmonization Group (IGHG) recommends that CCS treated with a known
78 ototoxic treatment (cisplatin with or without high-dose carboplatin (> 1500
79 mg/m²), and/or head or brain radiotherapy ≥ 30 Gy) and their health-care
80 providers “should be aware of the risk of hearing loss” [1]. IGHG recommends
81 annual hearing tests until six years of age, biannual tests until twelve years, and
82 every five years thereafter [1].
83 Informing CCS about the risk for late effects related to their cancer treatment is
84 important to facilitate follow-up care and to manage long-term health [12,13].
85 Previous research in Switzerland suggests CCS have limited knowledge about
86 their risks for late effects [14–16]. Studies investigating information provision on
87 specific late effects, such as hearing loss, are lacking.

88 Using data from the HEAR-study, a health service research project on the
89 hearing of CCS, we first examined whether adult CCS who had received ototoxic
90 treatments were aware of their risk for hearing loss, and had had their hearing
91 evaluated as recommended. Second, we compared CCS who were aware of
92 hearing loss risk with those who were not to identify CCS at increased need for
93 information and support. Third, we investigated whether CCS currently
94 experience clinically relevant hearing loss and explored the associations between
95 awareness, hearing evaluation after end of treatment, and current hearing loss
96 based on audiometric testing.

97 **4. Methods**

98 **4.1 Study population**

99 Eligible CCS were identified through the Swiss Childhood Cancer Registry
100 (ChCR). The ChCR is a national registry that includes all Swiss residents
101 diagnosed with leukemias, lymphomas, central nervous system (CNS) tumors,
102 malignant solid tumors, or Langerhans cell histiocytosis before 20 years of age
103 since 1976 [17,18]. We included CCS registered in the ChCR who had survived
104 at least two years since diagnosis, had received ototoxic treatment as defined
105 per IGHG guidelines, and were ≥ 18 years at the time of study. We excluded
106 CCS who lacked a valid address, were living outside Switzerland, did not speak
107 German or French, and had been contacted for another study in the past six
108 months (January 2022-July 2022). The Ethics Committee of the Canton of Bern
109 approved the ChCR (166/2014) and the HEAR-study (2021-01624).

110

111 **4.2 Procedures and study design**

112 The HEAR-study is a health service research project set up in 2021 at the
113 University of Bern, Switzerland. Details have been published previously [19].
114 Eligible CCS were invited by postal mail; we sent up to three reminders to CCS
115 who did not respond. CCS who responded with informed consent received an e-
116 mail request to complete an online questionnaire (Supplementary Table S6) and
117 an invitation to attend a free hearing test. Participants performed hearing tests at
118 a local hearing aid shop where a certified acoustician performed bilateral pure-

119 tone audiometry (125-8000Hz) with an additional bone conduction measurement
120 (250-4000Hz) if the hearing threshold was > 25dB. We collected questionnaires
121 and audiograms between July 15, 2022, and July 15, 2023.

122

123 **4.3 Hearing-related information**

124 *4.3.1 Awareness about the risk of hearing loss and information on prior* 125 *hearing evaluations*

126 We assessed awareness about the risk of hearing loss using a questionnaire.
127 We asked participants if they had been informed about an increased risk of
128 hearing loss (yes/no/don't know). We also asked if they had been counseled to
129 monitor their hearing after end of treatment (yes/no/don't know). If participants
130 answered yes to either of the two questions, we coded being informed as "yes".
131 Further, we asked if their hearing had ever been evaluated after end of treatment
132 (yes/no/don't know).

133 *4.3.2 Self-reported hearing loss, perceived hearing difficulties, and other late* 134 *effects*

135 We asked participants if they experienced any late effects of cancer or its therapy
136 (yes/no), and to list them. We created a variable "late effects other than hearing
137 loss" (yes/no) for which "no" indicated participants who only listed hearing loss or
138 nothing. If participants listed hearing loss as a late effect in the open question,
139 the variable on self-reported hearing loss was coded as "yes". Further, we asked
140 if they had problems following a conversation when there was background noise

141 (hearing difficulties in noisy environments) (yes/no) and if they felt they did not
142 hear well (feeling of poor hearing) (yes, often/yes, sometimes/no).

143 *4.3.3 Hearing loss from audiogram measurements*

144 The hearing aid shops sent us audiogram results in a coded file. For grading we
145 visualized the audiograms using the R package “audiometry” (Lehnbert B, R
146 package version 0.3.0, 2021) in RStudio (R Core Team, Vienna, AUT, 2022).
147 Two trained researchers (PJ and CN) independently graded audiograms for each
148 ear according to the SIOB Boston Ototoxicity Scale [20], an established grading
149 scheme used for CCS exposed to ototoxic treatments [21,22]. We resolved
150 discrepancies through discussions with an experienced audiologist (MK). We
151 considered bone conduction measurements when there was consistently a
152 significant difference between air and bone conduction measurements (≥ 10 dB),
153 indicating a potential conductive hearing loss [20]. We used the grading of the
154 more affected ear. Severity was graded as (a) none (grade 0), (b) mild (grade 1),
155 (c) moderate (grade 2), or (d) severe hearing loss (\geq grade 3) [20]. Clinically
156 relevant hearing loss was defined as SIOB Boston grade ≥ 2 [20,22].

157

158 **4.4 Participant characteristics**

159 *4.4.1 Clinical and cancer-treatment related characteristics*

160 The ChCR provided data on biological sex, year of birth, cancer diagnosis, age at
161 diagnosis, year of diagnosis, and type of therapy including carboplatin
162 chemotherapy, cisplatin chemotherapy, and cranial radiation.

163

164 *4.4.2 Information on follow-up care*

165 We asked participants in the questionnaire if they were still undergoing clinical
166 follow-up care related to their cancer (yes/no), and if they had received any
167 information regarding follow-up care in general (yes/no/don't know).

168

169 *4.4.3 Socioeconomic characteristics*

170 The questionnaire assessed sociodemographic characteristics including
171 migration background (yes/no), participants' and their parents' education levels,
172 and language region (German/French). Participants were categorized as having
173 a migration background if at least one parent was born outside Switzerland. We
174 defined three education level categories: primary schooling (compulsory
175 schooling only, ≤ 9 years), secondary education (vocational training, upper
176 secondary education), and tertiary education (university, or technical college).

177

178 **4.5 Statistical analysis**

179 First, we assessed how many CCS were aware of a risk of hearing problems
180 (information status) and how many had completed a hearing evaluation after the
181 end of treatment. For further analysis, we combined the categories "no" and
182 "don't know" interpreting both as insufficient awareness. Next, we assessed
183 severity of hearing loss and prevalence of clinically relevant hearing loss (SIOP
184 Boston Grade ≥ 2). Using univariable logistic regression, we investigated factors

185 associated with information status and having completed a hearing evaluation
186 after end of treatment (Supplementary Tables S4 and S5). We included sex, age
187 at study, time since diagnosis, age at diagnosis, year of diagnosis, language
188 region, participant and parental education, migration background, presence of
189 late effects other than hearing loss, self-reported hearing loss, general
190 information received on follow-up care, attending regular follow-up care visits,
191 and treatment (only platinum/only cranial radiation ≥ 30 Gy/both platinum and
192 cranial radiation) as explanatory variables. We categorized year of diagnosis into
193 the periods before and after 1995, reflecting a cut-off after which a decline in
194 hearing loss was observed in previous studies of CCS from Switzerland [7].
195 Information status was included as an additional explanatory variable for the
196 outcome hearing evaluation. In a multivariable logistic regression, we included all
197 exposures associated with the outcome at a significance level of $p \leq 0.1$. If there
198 were missing values in independent or dependent variables, we performed
199 complete case analyses.

200

201

202 **5. Results**

203 **5.1 Study population**

204 Of 573 eligible CCS exposed to ototoxic treatments, identified through the ChCR,
205 424 were invited to the study. One-hundred and five (25%) consented and
206 completed the questionnaire and 83 (20%) also completed a hearing test as part
207 of our study (Supplementary Figure SF1). About half (n=57, 54%) of participants
208 were female, median age at study start was 32 years (interquartile range [IQR]:
209 24-37), age at diagnosis 8 years (IQR: 4-13), and median time since diagnosis
210 23 years (IQR: 19-32) (Table 1). Common diagnoses were malignant bone
211 tumors (n=24, 23%), CNS tumors (n=23, 22%) and soft tissue sarcomas (n=22,
212 21%). Eighty CCS (76%) had been treated with platinum chemotherapy, and 41
213 (39%) with cranial radiation (Supplementary Table S2). Compared to
214 nonparticipants, CCS completing the questionnaire were more often female,
215 older at time of study, and further away from diagnosis (Supplementary Table
216 S1).

217

218

219

220

221

222

223

224

225 **TABLE 1** Characteristics of participants completing the questionnaire (N=105).

	Completed questionnaire N=105 n (%)
Sex	
Female	57 (54)
Male	48 (46)
<i>Age at study, years (Median, IQR)</i>	32 (24-37)
<i>Year of diagnosis (Median, range)</i>	1998 (1977-2018)
1977-1995	41 (39)
1996-2005	46 (44)
2006-2018	18 (17)
<i>Time since diagnosis, years (Median, IQR)</i>	23 (19-32)
<i>Age at cancer diagnosis, years (Median, IQR)</i>	8 (4-13)
<i>Diagnostic group of primary neoplasm (ICCC-3)</i>	
Leukemias	0 (0)
Lymphomas	7 (7)
CNS tumors	23 (22)
Neuroblastoma	13 (12)
Retinoblastoma	3 (3)
Renal tumors	2 (2)
Hepatic tumors	4 (4)
Malignant bone tumors	24 (23)
Soft tissue sarcomas	22 (21)
Germ cell tumors	7 (7)
Other	0 (0)
<i>Platinum Chemotherapy</i>	
No platinum chemotherapy	23 (22)
Cisplatin	42 (40)
Carboplatin	17 (16)
Cisplatin & Carboplatin	21 (20)
Unknown	2 (2)
<i>Cranial radiation</i>	
No cranial radiation	64 (61)
<30 Gray	0 (0)
≥30 Gray	41 (39)
Unknown	0 (0)
<i>Education</i>	
Primary schooling	5 (5)
Secondary education	57 (54)
Tertiary education	43 (41)

226
227
228
229

Abbreviations: IQR, Interquartile range. n, number. ICCC-3, international classification of childhood cancer, edition 3

230 **5.2 Information status and prior hearing evaluation**

231 Among 105 participants, 46 (44%, 95% confidence interval [CI]: 35-54%)
232 reported having received information or advice regarding risk of hearing loss or
233 necessity of conducting hearing tests after end of treatment, while 31 (30%, 95%
234 CI: 22-39%) reported not having received information/advice and 28 (27%, 95%
235 CI: 19-36%) did not remember (Figure 1). Similarly, 40 (38%, 95% CI: 29-48%)
236 participants reported having completed a hearing evaluation after end of
237 treatment, 34 (32%, 95% CI: 24-42%) reported not having completed a hearing
238 evaluation, and 31 (30%, 95% CI: 22-39%) did not remember. Of the 40
239 participants reporting a hearing evaluation, 13 (33%) had done it in the last 5
240 years, 12 (30%) longer ago, and 15 (38%) did not remember the year of their last
241 hearing evaluation (Supplementary Table S3).

242 We visualized the relationship between information status and prior hearing
243 evaluation using a proportional Venn diagram (Figure 1). Most CCS who were
244 informed also had their hearing evaluated at some point after treatment.

245

246 **5.3 Degree of hearing loss and information status, self-reported hearing** 247 **loss, and prior hearing evaluation**

248 Of 83 participants who completed a hearing test for the study, 29 had normal
249 hearing (35%, 95% CI: 25-46), 17 (20%, 95% CI: 13-31%) had mild, 11 (13%,
250 95% CI: 7-23%) moderate, and 26 (31%, 95% CI: 22-42%) severe hearing loss,
251 resulting in 37 participants (45%, 95% CI: 34-56%) with clinically relevant hearing
252 loss. Among the 36 participants with clinically relevant hearing loss who

253 completed the questionnaire, 20 (56%, 95% CI: 39-71%) reported having
254 received information/advice regarding their risk for hearing loss and 14 (39%,
255 95% CI: 24-56%) reported having had their hearing evaluated after end of
256 treatment. Further, 19 (53%, 95% CI: 36-69%) of the participants with clinically
257 relevant hearing loss reported prior hearing problems in the questionnaire, 29
258 (81%, 95% CI: 64-91%) reported hearing difficulties in noisy environments, and
259 30 (83%, 95% CI: 67-93%) sometimes or often felt like they were not hearing
260 well. (Figure 2)

261

262 **5.4 Factors associated with information status and hearing evaluation** 263 **after end of treatment**

264 Participants informed about risk of hearing loss were diagnosed more often after
265 1995 (odds ratio [OR]: 4.5, 95% CI: 1.3-15.4), reported more prior hearing
266 problems (OR: 10.9, 95% CI: 2.6-45.1) and other late effects (OR: 4.1, 95% CI:
267 1.3-13.2), and were more often treated with platinum chemotherapy (OR: 10.8,
268 95% CI: 2.2-53.2) or both platinum chemotherapy and cranial radiotherapy (OR:
269 6.5, 95% CI: 1.0-41.8) compared to cranial radiotherapy alone (Table 2). Those
270 who were informed were more likely to have had their hearing evaluated after
271 end of treatment (OR: 13.6, 95% CI: 3.8-48.3).

272

273

274

275

276

277 **TABLE 2** Factors associated with a) having received information/advice about
278 hearing loss, and b) having ever completed a hearing evaluation after therapy;
279 results from multivariable regressions.

Multivariable (95%-CI)	Informed/Advised ^{a,b}	Hearing evaluated ^{a,b}
	N=102	N=102
	OR (95%-CI)	OR (95%-CI)
<i>Period of cancer diagnosis</i>		
≤1995	1.0	1.0
>1995	4.5 (1.3-15.4)	2.2 (0.6-8.5)
<i>Late effects other than hearing loss</i>		
No	1.0	1.0
Yes	4.1 (1.3-13.2)	2.8 (0.8-9.6)
<i>Self-reported hearing loss</i>		
No	1.0	1.0
Yes	10.9 (2.6-45.1)	0.7 (0.2-2.7)
<i>Maternal education</i>		
Primary or secondary education	1.0	1.0
Tertiary education	1.7 (0.5-5.5)	1.6 (0.5-5.3)
<i>General information received on follow-up care</i>		
No	1.0	1.0
Yes	1.1 (0.4-3.3)	1.3 (0.4-4.4)
<i>Information/advice received on hearing loss and hearing screening</i>		
No	‡	1.0
Yes	‡	13.6 (3.8-48.3)
<i>Regular visit of follow-up care</i>		
No	1.0	1.0
Yes	1.9 (0.6-6.6)	1.0 (0.2-3.8)
<i>Treatment group</i>		
Cranial radiation ≥30 Gray only	1.0	1.0
Platinum Chemotherapy only	10.8 (2.2-53.2)	1.8 (0.3-9.4)
Both	6.5 (1.0-41.8)	0.9 (0.1-6.4)

280

281 The respective multivariable model was adjusted for variables with a p-value of 0.1 or
282 less in the univariable logistic regression.

283 ^a, People with missing maternal education and missing treatment group were excluded
284 from the logistic regression (n=3).

285 ^b, Age at study start and years since diagnosis were omitted from multivariable
286 regression for collinearity with year of diagnosis.

287 ‡, Exposure equal to outcome

288 Abbreviations: CI, Confidence Interval. OR, Odds Ratio. n, number.

289

290 **6. Discussion and Conclusion**

291 **6.1 Summary of findings**

292 This study found that over half of CCS who received ototoxic treatment reported
293 they were unaware of the risk of hearing loss even though international
294 guidelines recommend that they be aware. More than half did not remember
295 having ever had their hearing evaluated after end of treatment. We found a
296 strong association between being informed and having had a hearing evaluation.
297 Almost half of participants had clinically relevant hearing loss assessed by pure-
298 tone audiometry, yet almost half of those did not report hearing problems in the
299 questionnaire, which suggests they were not aware of their hearing loss.

300

301 **6.2 Information status**

302 Previous surveys on information provision and information needs among Swiss
303 CCS show that approximately one-third of survivors do not remember having
304 ever received general information about potential late effects of their cancer or
305 therapy, and about 80% of CCS wish to be better informed [14–16]. In this study,
306 56% of CCS did not remember receiving information about the risk for hearing
307 loss. This is comparable to a Norwegian study about information provision in
308 which up to 60% of cancer survivors overall did not recall receiving information
309 on late effects including hearing loss, though the study also included survivors
310 without ototoxic treatments [12]. A study from Hong Kong assessing knowledge
311 about risk-based, exposure-related late effects found that, similar to our study,

312 almost 60% of CCS were not aware of potential hearing problems following
313 ototoxic treatments [13].

314

315 *6.2.1 Associations with information status*

316 Consistent with other studies [12,14,15], we found that CCS seem to be less well
317 informed the more time has passed since diagnosis. A reason for this might be
318 that parents of patients who were younger children were the primary recipients of
319 information [23]. Parents might not have passed on the information to their
320 children, or CCS may have forgotten it given a long median time of 22 years
321 since diagnosis.

322 We found that CCS diagnosed after 1995 were better informed, which is likely
323 due to advances in knowledge about long-term effects of ototoxic treatments. For
324 example, the American Speech-Language-Hearing Association (ASHA) guideline
325 from 1994 recommended monitoring the hearing at least until one year post-
326 treatment with platinum agents and only longer if hearing loss was detected [24].
327 Considering that one-third of our study population was diagnosed before 1995,
328 they likely received outdated or limited information about potential long-term
329 effects.

330 The 1994 ASHA guideline further stated that cranial radiation alone has little
331 effect on hearing [24], and many clinicians might be less aware of the effect of
332 cranial radiation on hearing than platinum chemotherapy. This might explain why
333 participants who received cranial radiation ≥ 30 Gy alone were less informed
334 than participants treated with platinum agents. This aligns with a previous record-

335 based study in which we found that CCS treated with cranial radiation ≥ 30 Gy
336 were less likely to have received post-therapy hearing evaluations than CCS
337 treated with platinum chemotherapy [25]. Participants reporting other late effects
338 were more informed about the risk of hearing loss, suggesting that CCS with
339 multiple late effects are generally more aware of treatment-related complications
340 [26].

341

342 **6.3 Hearing evaluations after end of treatment**

343 A retrospective, record-based study examining audiological evaluations post-
344 therapy in Switzerland found that 28% of CCS at risk for hearing loss had not had
345 any hearing evaluations after end of treatment [25]. This is comparable to the
346 32% observed in our study. In our study, a further 30% did not recall undergoing
347 any hearing evaluations. While they might have had an initial test, CCS may not
348 have had subsequent assessments when their hearing test result was normal as
349 specified in older ASHA and Children's Oncology Group Long-Term Follow-Up
350 Guidelines [24,27]. Given that initial hearing tests often occur during or soon after
351 treatment, many may have forgotten about them or were not contacted for later
352 hearing evaluations as currently recommended [1].

353

354 **6.4 Degree of hearing loss and self-reported hearing loss**

355 We previously reported that 36% of CCS had clinically relevant hearing loss after
356 platinum-based therapy according to the SIOP Boston ototoxicity scale [28]. This

357 new study finds a higher prevalence (47%) of clinically relevant hearing loss,
358 likely because of different characteristics of the study population, which now is
359 older and further from diagnosis and more recently represents the survivor
360 cohort. Considering the newer study's low response rate, selection bias could
361 have also played a role in the difference.

362 Almost half of our study participants with clinically relevant hearing loss did not
363 report hearing problems as late effects in the questionnaire, suggesting they
364 were not aware of them. The proportion of participants with hearing problems by
365 SIOP Boston grade who did not self-report hearing loss was higher than that
366 found in a previous study in which we compared questionnaire-reported hearing
367 loss with audiometry results [29]. In that study, only 14% of CCS who did not self-
368 report hearing loss had hearing loss in the SIOP-Boston grade range from 1 to 4.
369 In the current study, self-reported hearing loss was assessed using an open
370 question about known late effects. We have potentially underestimated the
371 proportion of participants who are aware about their hearing loss since some
372 participants with hearing loss may not have listed it as a late effect.

373 **6.5 Strengths and limitations**

374 A strength of this study is the population-based sample with comprehensive
375 cancer-related medical data provided by the Swiss ChCR. Combined with the
376 questionnaire-based information and recent audiograms, our dataset allowed for
377 a thorough analysis. Study limitations include the response rate of 25% which, as
378 noted above, potentially introduced a selection bias. However, although analyses
379 revealed some statistically significant differences between responders and

380 nonresponders regarding cancer-related characteristics, differences were modest
381 based upon effect sizes. The low response rate may be due to the study settings
382 as CCS had not only to return a questionnaire but also visit a hearing aid shop
383 for a hearing test.

384

385 **6.6 Conclusion**

386 A large proportion of CCS are not aware of the potential risk of hearing loss due
387 to their treatment. Among those who are aware of this late effect, most have
388 undergone hearing evaluations. From this we conclude that knowledge is key to
389 timely interventions that can mitigate the effects of hearing loss. Caregivers,
390 parents, and CCS should always have the latest information on late effects and
391 follow-up care at hand to manage and protect auditory health throughout the lives
392 of CCS—even those with decades intervening since treatment.

393

394 **6.7 Practice implications**

395 How do we best manage survivorship to follow up treatment and address
396 potential late effects? In addition to direct, clinical support of CCS and parents,
397 electronic patient records continue to evolve and will improve the retention and
398 support the acquisition of knowledge accessible by both providers and patients.
399 A specific proposal for enhancing information access and retention for CCS is the
400 Survivorship Passport, or SurPass [30]. This tool can provide crucial details
401 about a survivor's medical history and a tailored plan for follow-up to caregivers,

402 and information for CCS that can inform their own decision-making; accessible
403 online, it can be continually updated by new research findings. Highly secure yet
404 accessible electronic records such as the SurPass can sustain awareness
405 among caregivers and CCS wherever their journey through survivorship takes
406 them.

407

408 **7. Abbreviations**

409 ASHA American Speech-Language-Hearing Association

410 CCS Childhood cancer survivor

411 COG Children’s Oncology Group

412 CI Confidence interval

413 IQR Interquartile range

414 Gy Gray

415

416 **8. Acknowledgements**

417 We thank the study team of the Childhood Cancer Research Group, Institute of
418 Social and Preventive Medicine, University of Bern, the Swiss Childhood Cancer
419 Survivor Study, and the team of the Swiss Childhood Cancer Registry. We thank
420 Christopher Ritter from the editorial service of the Institute of Social and
421 Preventive Medicine at the University of Bern for the editorial suggestions. We
422 thank all childhood cancer survivors participating in the study.

423

424 **9. CRediT authorship contribution statement**

425 **Philippa Jörger:** formal analysis, investigation, writing—original draft, review &
426 editing, visualization, project administration. **Carina Nigg:** formal analysis,
427 writing—original draft, review & editing, supervision. **Maša Žarković:** formal
428 analysis, writing—original draft, review & editing. **Grit Sommer:** writing—review
429 & editing. **Martin Kompis:** formal analysis, writing—review & editing, funding
430 acquisition. **Gisela Michel:** writing—review & editing, funding acquisition. **Marc**
431 **Ansari:** conceptualization, writing—review & editing, supervision, funding
432 acquisition. **Nicolas Waespe:** writing—review & editing, funding acquisition.
433 **Claudia Kuehni:** conceptualization, methodology, formal analysis, writing—
434 review & editing, supervision, project administration, funding acquisition.

435

436 **10. Funding sources**

437 This work was financially supported by the Swiss Cancer League and Swiss
438 Cancer Research (grant number HSR-4951-11-2019, KLS/KFS-5711-01-2022,
439 and KFS-5302-02-2021). The CANSEARCH foundation, Kinderkrebs Schweiz
440 Foundation, and Zoé4Life Foundation supported NW.

441 **11. Declaration of competing interest**

442 Nicolas Waespe reports a relationship with Swedish Orphan Biovitrum AB that
443 includes advisory board membership, consulting, and travel reimbursement and
444 a relationship with Novartis that includes advisory board membership. None of
445 these relationships are in association with the current study.

446 **12. References**

- 447 [1] E. Clemens, M.M. van den Heuvel-Eibrink, R.L. Mulder, L.C.M. Kremer,
448 M.M. Hudson, R. Skinner, L.S. Constine, J.K. Bass, C.E. Kuehni, T.
449 Langer, E.C. van Dalen, E. Bardi, N.-X. Bonne, P.R. Brock, B. Brooks, B.
450 Carleton, E. Caron, K.W. Chang, K. Johnston, K. Knight, P.C. Nathan, E.
451 Orgel, P.K. Prasad, J. Rottenberg, K. Scheinmann, A.C.H. de Vries, T.
452 Walwyn, A. Weiss, A. Am Zehnhoff-Dinnesen, R.J. Cohn, W. Landier,
453 International Guideline Harmonization Group ototoxicity group,
454 Recommendations for ototoxicity surveillance for childhood, adolescent,
455 and young adult cancer survivors: a report from the International Late
456 Effects of Childhood Cancer Guideline Harmonization Group in
457 collaboration with the PanCare Consortium., *Lancet Oncol* 20 (2019) e29–
458 e41. [https://doi.org/10.1016/S1470-2045\(18\)30858-1](https://doi.org/10.1016/S1470-2045(18)30858-1).
- 459 [2] L.K. Dillard, L. Lopez-Perez, R.X. Martinez, A.M. Fullerton, S. Chadha,
460 C.M. McMahon, Global burden of ototoxic hearing loss associated with
461 platinum-based cancer treatment: A systematic review and meta-analysis.,
462 *Cancer Epidemiol* 79 (2022) 102203.
463 <https://doi.org/10.1016/j.canep.2022.102203>.
- 464 [3] B. Murphy, A. Jackson, J.K. Bass, D.S. Tsang, C.M. Ronckers, L. Kremer,
465 S. Baliga, A. Olch, A.H. Zureick, K.-W. Jee, L.S. Constine, T.I. Yock,
466 Modeling the Risk of Hearing Loss From Radiation Therapy in Childhood
467 Cancer Survivors: A PENTEC Comprehensive Review., *Int J Radiat Oncol*
468 *Biol Phys* 119 (2024) 446–456. <https://doi.org/10.1016/j.ijrobp.2023.08.016>.

25-Sep-24

- 469 [4] D.L. Kwong, W.I. Wei, J.S. Sham, W.K. Ho, P.W. Yuen, D.T. Chua, D.K.
470 Au, P.M. Wu, D.T. Choy, Sensorineural hearing loss in patients treated for
471 nasopharyngeal carcinoma: a prospective study of the effect of radiation
472 and cisplatin treatment., *Int J Radiat Oncol Biol Phys* 36 (1996) 281–9.
473 [https://doi.org/10.1016/s0360-3016\(96\)00302-1](https://doi.org/10.1016/s0360-3016(96)00302-1).
- 474 [5] J.K. Bass, C.-H. Hua, J. Huang, A. Onar-Thomas, K.K. Ness, S. Jones, S.
475 White, S.P. Bhagat, K.W. Chang, T.E. Merchant, Hearing Loss in Patients
476 Who Received Cranial Radiation Therapy for Childhood Cancer., *J Clin*
477 *Oncol* 34 (2016) 1248–55. <https://doi.org/10.1200/JCO.2015.63.6738>.
- 478 [6] G.B. Williams, L.E. Kun, J.W. Thompson, H.J. Gould, R.M.S. Stocks,
479 Hearing loss as a late complication of radiotherapy in children with brain
480 tumors., *Ann Otol Rhinol Laryngol* 114 (2005) 328–31.
481 <https://doi.org/10.1177/000348940511400413>.
- 482 [7] A. Weiss, G. Sommer, R. Kasteler, K. Scheinemann, M. Grotzer, M.
483 Kompis, C.E. Kuehni, Swiss Pediatric Oncology Group (SPOG), Long-term
484 auditory complications after childhood cancer: A report from the Swiss
485 Childhood Cancer Survivor Study., *Pediatr Blood Cancer* 64 (2017) 364–
486 373. <https://doi.org/10.1002/pbc.26212>.
- 487 [8] J.K. Bass, W. Liu, P. Banerjee, T.M. Brinkman, D.A. Mulrooney, A. Gajjar,
488 A.S. Pappo, T.E. Merchant, G.T. Armstrong, D. Srivastava, L.L. Robison,
489 M.M. Hudson, K.R. Krull, Association of Hearing Impairment With
490 Neurocognition in Survivors of Childhood Cancer., *JAMA Oncol* 6 (2020)
491 1363–1371. <https://doi.org/10.1001/jamaoncol.2020.2822>.

25-Sep-24

- 492 [9] A. Weiss, G. Sommer, C. Schindera, L. Wengenroth, A. Karow, M. Diezi,
493 G. Michel, C.E. Kuehni, Swiss Paediatric Oncology Group (SPOG),
494 Hearing loss and quality of life in survivors of paediatric CNS tumours and
495 other cancers., *Qual Life Res* 28 (2019) 515–521.
496 <https://doi.org/10.1007/s11136-018-2021-2>.
- 497 [10] M. Khairi Md Daud, R.M. Noor, N.A. Rahman, D.S. Sidek, A. Mohamad,
498 The effect of mild hearing loss on academic performance in primary school
499 children., *Int J Pediatr Otorhinolaryngol* 74 (2010) 67–70.
500 <https://doi.org/10.1016/j.ijporl.2009.10.013>.
- 501 [11] S. Strebler, K. Baust, D. Grabow, J. Byrne, T. Langer, A. Am Zehnhoff-
502 Dinnesen, R. Kuonen, A. Weiss, T. Kepak, J. Kruseova, C. Berger, G.
503 Calaminus, G. Sommer, C.E. Kuehni, PanCareLIFE Consortium, Auditory
504 complications among childhood cancer survivors and health-related quality
505 of life: a PanCareLIFE study., *J Cancer Surviv* (2023) 1–12.
506 <https://doi.org/10.1007/s11764-023-01456-4>.
- 507 [12] M.E. Gianinazzi, C.E. Kiserud, E. Ruud, H.C. Lie, Who Knows? Information
508 Received, and Knowledge about, Cancer, Treatment and Late Effects in a
509 National Cohort of Long-Term Childhood, Adolescent and Young Adult
510 Cancer Survivors., *Cancers* (Basel) 14 (2022) 1534.
511 <https://doi.org/10.3390/cancers14061534>.
- 512 [13] C.-T. Ma, H.W. Chou, T.T.-N. Lam, Y.T. Tung, Y.W. Lai, L.-K. Lee, V.W.-Y.
513 Lee, N.C.-Y. Yeung, A.W.-K. Leung, S. Bhatia, C.K. Li, Y.T. Cheung,
514 Provision of a personalized survivorship care plan and its impact on

-
- 515 cancer-related health literacy among childhood cancer survivors in Hong
516 Kong., *Pediatr Blood Cancer* 70 (2023) e30084.
517 <https://doi.org/10.1002/pbc.30084>.
- 518 [14] M.E. Gianinazzi, S. Essig, C.S. Rueegg, N.X. von der Weid, P. Brazzola,
519 C.E. Kuehni, G. Michel, Swiss Paediatric Oncology Group (SPOG),
520 Information provision and information needs in adult survivors of childhood
521 cancer., *Pediatr Blood Cancer* 61 (2014) 312–8.
522 <https://doi.org/10.1002/pbc.24762>.
- 523 [15] S. Christen, E. Weishaupt, J. Vetsch, C.S. Rueegg, L. Mader, S. Dehler, G.
524 Michel, Perceived information provision and information needs in
525 adolescent and young adult cancer survivors., *Eur J Cancer Care (Engl)* 28
526 (2019) e12892. <https://doi.org/10.1111/ecc.12892>.
- 527 [16] Y. Sievers, K. Roser, K. Scheinemann, G. Michel, A. Ilic, The information
528 needs of relatives of childhood cancer patients and survivors: A systematic
529 review of quantitative evidence., *Patient Educ Couns* 126 (2024) 108316.
530 <https://doi.org/10.1016/j.pec.2024.108316>.
- 531 [17] Childhood Cancer Registry, Childhood Cancer Registry (ChCR), (2023).
532 <https://www.childhoodcancerregistry.ch/> (accessed August 1, 2023).
- 533 [18] G. Michel, N.X. von der Weid, M. Zwahlen, M. Adam, C.E. Rebholz, C.E.
534 Kuehni, Swiss Childhood Cancer Registry, Swiss Paediatric Oncology
535 Group (SPOG) Scientific Committee, The Swiss Childhood Cancer
536 Registry: rationale, organisation and results for the years 2001-2005.,

-
- 537 Swiss Med Wkly 137 (2007) 502–9.
538 <https://doi.org/10.4414/smw.2007.11875>.
- 539 [19] P. Jörger, C. Nigg, L. Mader, S. Strebler, M. Kompis, Z. Tomášiková, C.
540 Schindera, G. Michel, N.X. Von Der Weid, M. Ansari, N. Waespe, C.E.
541 Kuehni, Protocol for a low-threshold screening program to detect hearing
542 loss in childhood cancer survivors in Switzerland: The HEAR-study, JMIR
543 Preprints (2024). <https://doi.org/10.2196/preprints.63627>.
- 544 [20] P.R. Brock, K.R. Knight, D.R. Freyer, K.C.M. Campbell, P.S. Steyger, B.W.
545 Blakley, S.R. Rassekh, K.W. Chang, B.J. Fligor, K. Rajput, M. Sullivan,
546 E.A. Neuwelt, Platinum-induced ototoxicity in children: a consensus review
547 on mechanisms, predisposition, and protection, including a new
548 International Society of Pediatric Oncology Boston ototoxicity scale., J Clin
549 Oncol 30 (2012) 2408–17. <https://doi.org/10.1200/JCO.2011.39.1110>.
- 550 [21] A. Khan, A. Budnick, D. Barnea, D.R. Feldman, K.C. Oeffinger, E.S.
551 Tonorezos, Hearing Loss in Adult Survivors of Childhood Cancer Treated
552 with Radiotherapy., Children (Basel) 5 (2018) 59.
553 <https://doi.org/10.3390/children5050059>.
- 554 [22] D.J. Moke, C. Luo, J. Millstein, K.R. Knight, S.R. Rassekh, B. Brooks,
555 C.J.D. Ross, M. Wright, V. Mena, T. Rushing, A.J. Esbenshade, B.C.
556 Carleton, E. Orgel, Prevalence and risk factors for cisplatin-induced
557 hearing loss in children, adolescents, and young adults: a multi-institutional
558 North American cohort study., Lancet Child Adolesc Health 5 (2021) 274–
559 283. [https://doi.org/10.1016/S2352-4642\(21\)00020-1](https://doi.org/10.1016/S2352-4642(21)00020-1).


- 560 [23] S. Palmer, A. Mitchell, K. Thompson, M. Sexton, Unmet needs among
561 adolescent cancer patients: a pilot study., *Palliat Support Care* 5 (2007)
562 127–34. <https://doi.org/10.1017/s1478951507070198>.
- 563 [24] American Speech-Language-Hearing Association, Audiologic Management
564 of Individuals Receiving Cochleotoxic Drug Therapy, (1994).
565 <https://doi.org/10.1044/policy.GL1994-00003>.
- 566 [25] A. Weiss, R. Kuonen, H. Brockmeier, M. Grotzer, C. Candraia, R. Maire, P.
567 Senn, C. Stieger, J. Rosenfeld, D. Veraguth, M. Kompis, K. Scheinemann,
568 C.E. Kuehni, Swiss Pediatric Oncology Group (SPOG), Audiological
569 monitoring in Swiss childhood cancer patients., *Pediatr Blood Cancer* 65
570 (2018) e26877. <https://doi.org/10.1002/psc.26877>.
- 571 [26] C. Signorelli, C.E. Wakefield, J.E. Fardell, W.H.B. Wallace, E.G.
572 Robertson, J.K. McLoone, R.J. Cohn, The impact of long-term follow-up
573 care for childhood cancer survivors: A systematic review., *Crit Rev Oncol*
574 *Hematol* 114 (2017) 131–138.
575 <https://doi.org/10.1016/j.critrevonc.2017.04.007>.
- 576 [27] Children's Oncology Group, Long-Term Follow-Up Guidelines for Survivors
577 of Childhood, Adolescent, and Young Adult Cancers - Version 4.0, (2013).
578 www.survivorshipguidelines.org (accessed February 15, 2024).
- 579 [28] S. Strebler, L. Mader, T. Sláma, N. Waespe, A. Weiss, R. Parfitt, A. Am
580 Zehnhoff-Dinnesen, M. Kompis, N.X. von der Weid, M. Ansari, C.E.
581 Kuehni, Severity of hearing loss after platinum chemotherapy in childhood

582 cancer survivors., *Pediatr Blood Cancer* 69 (2022) e29755.
583 <https://doi.org/10.1002/pbc.29755>.

584 [29] A. Weiss, G. Sommer, R. Kuonen, K. Scheinemann, M. Grotzer, M.
585 Kompis, C.E. Kuehni, Swiss Paediatric Oncology Group (SPOG),
586 Validation of questionnaire-reported hearing with medical records: A report
587 from the Swiss Childhood Cancer Survivor Study., *PLoS One* 12 (2017)
588 e0174479. <https://doi.org/10.1371/journal.pone.0174479>.

589 [30] R. Haupt, S. Essiaf, C. Dellacasa, C.M. Ronckers, S. Caruso, E. Sugden,
590 L. Zadavec Zaletel, M. Muraca, V. Morsellino, A. Kienesberger, A.
591 Blondeel, D. Saraceno, M. Ortali, L.C.M. Kremer, R. Skinner, J. Roganovic,
592 F. Bagnasco, G.A. Levitt, M. De Rosa, M. Schrappe, L. Hjorth, R.
593 Ladenstein, PanCareSurFup, ENCCA Working Group, ExPo-r-Net Working
594 Group, The “Survivorship Passport” for childhood cancer survivors., *Eur J*
595 *Cancer* 102 (2018) 69–81. <https://doi.org/10.1016/j.ejca.2018.07.006>.
596

597



598 **FIGURE 1** Participant responses to questions on awareness and prior hearing evaluation.


599
600 Participants who reported (a) having been informed or advised about the possibility of hearing loss and the need for hearing tests after completing
601 therapy and (b) having had a hearing evaluation after completing the therapy. Proportional Venn-Diagram depicting the relation between having
602 been informed or advised and having had a hearing evaluation.

603 Numbers represent the number (n) and percentage (%) of participants reporting yes to the respective question; (a) Informed/Advised, Were you
604 informed about hearing loss as a potential late effect of your treatment / Have you been advised to have your hearing checked after completing

605 your therapies? (b) Hearing evaluated, Has your hearing ever been checked after you finished your treatment? No/Don't know; Answered no or do
606 not know to both questions.

607 Abbreviations: n, number.

608 **FIGURE 2** Degree of hearing loss assessed with audiograms and
609 graded according to SIOP Boston ototoxicity scale, and responses of
610 questions on awareness with clinically relevant hearing loss (Grade
611 ≥ 2).



612

613 (left) Degree of hearing loss according to SIOP Boston Ototoxicity Scale for participants with
614 available audiograms, N=83. No hearing loss, grade 0. Mild, grade 1. Moderate, grade 2. Severe,
615 \geq grade 3.


616 (right) Participants with clinically relevant hearing loss (SIOP Boston ototoxicity scale ≥ 2 , n=36)
617 who completed the baseline questionnaire and status on information/advice received on hearing
618 loss (yes/no), hearing evaluated after therapy end (yes/no), self-reported hearing loss (yes/no),
619 hearing difficulties in noisy environments (yes/no) and feeling of bad hearing (yes/no). 95%
620 Confidence intervals are displayed for those reporting “Yes”.

621 ^a, Participants with clinically relevant hearing loss who did not complete the baseline
622 questionnaire were excluded from this graphic (n=1).

623 Abbreviations: SIOP, International Society of Paediatric Oncology. n, number.

624

625 **Supplementary FIGURE SF1** Flowchart illustrating the HEAR-study
626 population, depicting eligible survivors identified by the Swiss
627 Childhood Cancer Registry.
628



629

630 Abbreviations: ICCC-3, international classification of childhood cancer, edition 3. n,
631 number.

632

633 **Supplementary TABLE S1** Demographic and clinical characteristics
634 of study population, stratified by response status.

	Total invited N=424	Completed questionnaire N=105	Did not respond to questionnaire N=319	p-value ^a	Cramér's V / Cohen's d ^b
	<i>n (%)</i>	<i>n (%)</i>	<i>n (%)</i>		
Sex				0.08	0.08
Female	199 (47)	57 (54)	142 (45)		
Male	225 (53)	48 (46)	177 (55)		
Age at study, years (Median, IQR)	29 (23-37)	32 (24-37)	29 (22-36)	0.03	0.24
18-25	148 (35)	33 (31)	115 (36)		
26-34	141 (33)	31 (30)	110 (34)		
35-57	135 (32)	41 (39)	94 (29)		
Year of diagnosis (Median, range)	1999 (1977-2019)	1998 (1977-2018)	2000 (1978-2019)	0.02	0.25
1977-1995	147 (35)	33 (31)	114 (36)		
1996-2003	153 (36)	39 (37)	114 (36)		
2004-2019	124 (29)	33 (31)	91 (29)		
Time since diagnosis, years (Median, IQR)	22 (16-30)	23 (19-32)	21 (16-29)	0.03	0.25
3-18	143 (34)	25 (24)	118 (37)		
19-26	144 (34)	40 (38)	104 (33)		
27-44	137 (32)	40 (38)	97 (30)		
Age at cancer diagnosis, years (Median, IQR)	9 (3.5-13)	8 (4-13)	9 (3-13)	0.87	0.02
≤5	147 (35)	33 (31)	114 (36)		
6-12	153 (36)	39 (37)	114 (36)		
13-20	124 (29)	33 (31)	91 (29)		
Diagnostic group of primary neoplasm (ICCC-3)				0.01	0.23
Leukemias (I)	8 (2)	0 (0)	8 (3)		
Lymphomas (II)	17 (4)	7 (7)	10 (3)		
CNS (III)	111 (26)	23 (22)	88 (28)		
Neuroblastoma (IV)	42 (10)	13 (12)	29 (9)		
Retinoblastoma (V)	15 (4)	3 (3)	12 (4)		
Renal tumors (VI)	30 (7)	2 (2)	28 (9)		
Hepatic tumors (VII)	11 (3)	4 (4)	7 (2)		
Malignant bone tumors (VIII)	71 (17)	24 (23)	47 (15)		
Soft tissue (IX)	67 (16)	22 (21)	45 (14)		
Germ cell tumors (X)	49 (12)	7 (7)	42 (13)		
Other (XI)	3 (1)	0 (0)	3 (1)		
Platinum Chemotherapy				0.50	0.10
No platinum chemotherapy	91 (21)	23 (22)	68 (21)		
Cisplatin	148 (35)	42 (40)	106 (33)		
Carboplatin	92 (22)	17 (16)	75 (24)		
Cisplatin & Carboplatin	78 (18)	21 (20)	57 (18)		
Unknown	15 (4)	2 (2)	13 (4)		
Cranial radiation				0.57	0.07
No cranial radiation	253 (60)	64 (61)	189 (59)		
<30 Gray	3 (1)	0 (0)	3 (1)		
≥30 Gray	165 (39)	41 (39)	124 (39)		
Unknown	3 (1)	0 (0)	3 (1)		

635

636 Abbreviations: n, number. IQR, Interquartile Range. ICC-3, international classification
637 of childhood cancer, edition 3. CNS, central nervous system.

638 ^a, p-values calculated from chi-square statistics for categorical variables and two-sided t-
639 test for continuous variables, comparing responders to non-responders.

640 ^b, Effect sizes were calculated using Cramér's V for categorical and Cohen's d for
641 continuous variables.

642 **Supplementary TABLE S2** Clinical risk factors for hearing loss in
643 childhood cancer survivors who participated in the HEAR-study
644 (N=105).
645

	Cranial radiation ≥30 Gray n (%)	No cranial radiation n (%)	Total n (%)
Cisplatin	4 (10)	38 (59)	42 (40)
Carboplatin	7 (17)	10 (16)	17 (16)
Cisplatin & Carboplatin	6 (15)	15 (23)	21 (20)
No platinum chemotherapy	23 (56)	0 (0)	23 (22)
Unknown	1 (2)	1 (2)	2 (2)
Total	41 (100)	64 (100)	105 (100)

646
647

648 **Supplementary TABLE S3** Calendar period of last completed
649 hearing test (n=40).
650

Year	Participants N=40 (n, (%))
<2020	12 (30)
2020-2022	13 (33)
Do not remember	15 (38)

651
652
653

Abbreviations: n, number.

654 **Supplementary TABLE S4** Characteristics of participants by
655 information status and factors associated with information status;
656 results from univariable logistic regressions.
657

	Informed/Advised yes N=46	Informed/Advised no or don't know know N=59	Univariable OR (95%-CI) N=105	p-value
	<i>n (%)</i>	<i>n (%)</i>		
Sex				
Female	24 (52)	33 (56)	1.0	
Male	22 (48)	26 (44)	1.2 (0.5-2.5)	0.70
<i>Median age at study (IQR; Range)</i>	29 (22-35; 18-43)	34 (25-45; 19-57)	0.9 (0.9-1.0)	<0.01
<i>Median years since diagnosis (IQR; Range)</i>	20 (17-26; 4-43)	27 (22-34; 7-44)	0.9 (0.9-1.0)	<0.01
<i>Median age at diagnosis (IQR; Range)</i>	10 (4-14; 0-19)	7 (3-13; 0-19)	1.0 (1.0-1.1)	0.19
<i>Year of diagnosis (IQR; Range)</i>	2002 (1996-2005; 1979-2018)	1995 (1987-2000; 1977-2014)	1.1 (1.0-1.2)	<0.01
≤1995	11 (24)	30 (51)	3.3 (1.4-7.7)	<0.01
>1995	35 (76)	29 (49)		
Language region				0.20
French	11 (24)	21 (36)	1.0	
German	35 (76)	38 (64)	1.8 (0.7-4.2)	
Participant education				
Primary or secondary education	29 (63)	33 (56)	1.0	
Tertiary education	17 (37)	26 (44)	0.7 (0.3-1.6)	0.46
Maternal education^a				
Primary or secondary education	29 (63)	47 (80)	1.0	
Tertiary education	16 (35)	11 (19)	2.4 (1.0-5.8)	0.06
Missing	1 (2)	1 (2)	NA	NA
Paternal education^a				
Primary or secondary education	28 (61)	44 (75)	1.0	
Tertiary education	17 (37)	15 (25)	1.8 (0.8-4.1)	0.18
Missing	1 (2)	0 (0)	NA	NA
Migration background^a				
No	29 (63)	35 (59)	1.0	
Yes	17 (37)	22 (37)	0.9 (0.4-2.1)	0.87
Missing	0 (0)	2 (3)	NA	NA
Late effects other than hearing loss				
No	9 (20)	24 (41)	1.0	
Yes	37 (80)	35 (59)	2.8 (1.2-6.9)	0.02
Self-reported hearing loss				
No	27 (59)	54 (92)	1.0	
Yes	19 (41)	5 (8)	7.6 (2.6-22.6)	<0.01
General information received on follow-up care				
No	24 (52)	43 (73)	1.0	
Yes	22 (48)	16 (27)	2.5 (1.1-5.6)	0.03
Regular visit of follow-up care				
No	20 (43)	38 (64)	1.0	
Yes	26 (57)	21 (36)	2.4 (1.1-5.2)	0.03
Treatment groups				
Cranial radiation ≥30 Gray only	3 (7)	20 (34)	1.0	
Platinum Chemotherapy only	32 (70)	31 (53)	6.9 (1.9-25.5)	<0.01
Both	11 (24)	6 (10)	12.2 (2.5-58.7)	<0.01
Missing	0	2 (3)	NA	NA

658 ^a, People with missing maternal or paternal education, missing migration background
659 and missing cisplatin were excluded from the univariable logistic regression.

It is made available under a [CC-BY 4.0 International license](#) .

Manuscript – Awareness Hearing loss
25-Sep-24

Philippa Jörger

660 Abbreviations: N, number OR, Odds Ratio. CI, Confidence Interval. IQR, Interquartile
661 Range.

662 **Supplementary TABLE S5** Characteristics of participants by status
663 of prior hearing evaluation; results from univariable logistic
664 regressions.
665

	Hearing evaluated yes N=40 n (%)	Hearing evaluated no or didn't know N=65 n (%)	Univariable OR (95%-CI) N=105	p-value
Sex				
Female	22 (55)	35 (54)	1.0	
Male	18 (45)	30 (46)	1.0 (0.4-2.1)	0.91
Median age at study (IQR; Range)	29 (24-35; 18-48)	34 (24-43; 19-57)	1.0 (0.9-1.0)	0.036
Median years since diagnosis (IQR; Range)	21 (17-26; 4-41)	26 (20-34; 4-44)	0.9 (0.9-1.0)	0.013
Median age at diagnosis (IQR; Range)	9 (3-14; 0-19)	8 (4-13; 0-19)	1.0 (1.0-1.1)	0.57
Year of diagnosis (IQR; Range)	2000 (1996-2005; 1981-2018)	1996 (1988-2002; 1977-2017)	1.1 (1.0-1.1)	0.01
≤1995	9 (23)	32 (49)	3.3 (1.4-8.1)	<0.01
>1995	31 (78)	33 (51)		
Language region				
French	11 (28)	21 (32)	1.0	
German	29 (73)	44 (68)	1.3 (0.5-3.0)	0.60
Participant education				
Primary or secondary education	27 (68)	35 (54)	1.0	
Tertiary education	13 (33)	30 (46)	0.6 (0.2-1.3)	0.17
Maternal education^a				
Primary or secondary education	24 (60)	52 (80)	1.0	
Tertiary education	15 (38)	12 (18)	2.8 (1.1-6.8)	0.03
Missing	1 (3)	1 (2)	NA	NA
Paternal education^a				
Primary or secondary education	25 (63)	47 (72)	1.0	
Tertiary education	14 (35)	18 (28)	1.5 (0.6-3.4)	0.38
Missing	1 (3)	0 (0)	NA	NA
Migration background^a				
No	24 (60)	40 (62)	1.0	
Yes	16 (40)	23 (35)	1.2 (0.5-2.6)	0.72
Missing	0 (0)	2 (3)	NA	NA
Late effects other than hearing loss				
No	7 (18)	26 (40)	1.0	
Yes	33 (83)	39 (60)	3.1 (1.2-8.2)	0.02
Self-reported hearing loss				
No	27 (68)	54 (83)	1.0	
Yes	13 (33)	11 (17)	2.4 (0.9-6.0)	0.07
General information received on follow-up care				
No	20 (50)	47 (72)	1.0	
Yes	20 (50)	18 (28)	2.6 (1.1-6.0)	0.02
Information/advice received on hearing loss and hearing screening				
No	7 (18)	52 (80)	1.0	
Yes	33 (83)	13 (20)	18.9 (6.8-52.1)	<0.01
Regular visit of follow-up care				
No	18 (45)	40 (62)	1.0	
Yes	22 (55)	25 (38)	2.0 (0.9-4.3)	0.10
Treatment groups^a				
Cranial radiation ≥30 Gray only	4 (10)	19 (29)	1.0	
Platinum Chemotherapy only	28 (70)	35 (54)	3.8 (1.2-12.5)	0.03
Both	8 (20)	9 (14)	4.2 (1.0-17.8)	0.05

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

Manuscript – Awareness Hearing loss
25-Sep-24

Philippa Jörger

Missing	0 (0)	2 (3)	NA	NA
---------	-------	-------	----	----

666

667 ^a, People with missing maternal or paternal education, missing migration background

668 and missing platin status were excluded from the univariable logistic regression.

669 Abbreviations: N, number OR, Odds Ratio. CI, Confidence Interval. IQR, Interquartile

670 Range.

671 **Supplementary TABLE S6** Questions on late effects, hearing loss,
672 information provision, awareness of hearing loss, and
673 sociodemographic characteristics in from the HEAR-study (translated
674 into English).

675

Variable	Question in questionnaire	Answer options
Presence of late effects	Are you suffering from a late effect of your previous cancer or its treatment?	Yes; no
Self-reported hearing loss	What late effects do you suffer from?	Open
General information received regarding follow-up care	Have you received written or verbal information from your pediatric oncologists regarding follow-up care?	Yes; no; don't know
Information status	Have you been informed that hearing impairment or hearing loss is possible after completion of therapy?	Yes; no; don't know
	Have you been advised to have your hearing checked after completing your therapy?	Yes; no; don't know
Regular visit of follow-up care	Do you still go to regular check-ups or follow-up care for your cancer?	Yes; no
Prior hearing evaluation	Has your hearing been checked after you have completed your cancer treatment?	Yes; no; don't know
Participant education	What is the highest level of education you have completed?	Obligatory; vocational training; high school; technical college; university
Education mother/father	What is your mother's/father's highest level of education?	Obligatory; vocational training; high school; technical college; university
Birthplace mother/father	In which country was your mother/father born?	Switzerland; don't know; other
Feeling of bad hearing	Do you sometimes have the feeling of not hearing well?	Yes, often; yes, sometimes; no
Hearing difficulties in noisy environments	Do you have problems following conversations in background noise, in a group, in a restaurant or with background music?	Yes; no

676

677

678